TEVA Teva Pharmaceutical Industries
$40.48▲ +1.33%
Healthcare
Other
Volume 2.46M
Avg Volume (10D) 6.08M
Key Metrics & Fundamentals
Market Cap
$47.21B
P/E Ratio
67.5
Div Yield
0.00%
52W Range
19.23 - 42.02
% vs 50 MA
3.09%
% vs 200 MA
16.10%
RSI-14
51.2
MACD Histogram
-0.2200
Beta (1Y vs SPY)
0.75
Free Cash Flow
$307.00M
Gross Rev
$4.14B
Gross Profit
$2.15B
EBITDA
$379.00M
COGS
$1.99B
Operating Exp
$2.00B
Operating Income
$149.00M
EBIT
$149.00M
Pretax Income
-$455.00M
Net Income
-$576.00M
EPS (Diluted)
-0.49
Price & Volume History
Loading chart…
Recent News
Teva Pharmaceutical Industries Unit Buys Rights to BXCL501 From BioXcel Therapeutics
MT Newswires · Oct 27, 2026 10:07 AM ET
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Teva Pharmaceutical Industries (TEVA) Secured WELTRUZA Approval, Is It Still 16% Below Fair Value?
Simply Wall St. · Oct 23, 2026 5:13 PM ET
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
MarketBeat · Oct 23, 2026 2:04 PM ET
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Clinical Trials Arena · Oct 21, 2026 8:19 AM ET
Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says
MT Newswires · Oct 20, 2026 12:11 PM ET
Teva Pharmaceuticals, Sanofi Report Positive 44-Week Duvakitug Data in Ulcerative Colitis, Crohn's Disease
MT Newswires · Oct 20, 2026 10:02 AM ET
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
GlobeNewswire · Oct 20, 2026 8:00 AM ET
Israel Elections: AI Stocks, A Defense Winner And Oil Prices In Focus
Investor's Business Daily · Oct 15, 2026 8:00 AM ET
Nvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value Gems
Insider Monkey · Oct 13, 2026 11:34 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TEVA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.